Veille Pharma
20.7K views | +0 today
Veille Pharma
Chargé d'affaires chez Patientsworld. Mes posts n'engagent que moi.
Your new post is loading...
Your new post is loading...
Scooped by Alexandre DUBOIS
Scoop.it!

NCCN Modifies Guidelines For Multiple Myeloma A Second Time In 2011 - The Myeloma Beacon

NCCN Modifies Guidelines For Multiple Myeloma A Second Time In 2011 - The Myeloma Beacon | Veille Pharma | Scoop.it

Recently, the National Comprehensive Cancer Network (NCCN) announced several updates and changes to its guidelines for the diagnosis and treatment of multiple myeloma.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Millenium, Takeda Pharma Withdraw SNDA For Relapsed Follicular Lymphoma Therapy

Millenium, along with its parent company Takeda Pharmaceutical Co. Ltd. (TKPHF.PK: News ) Thursday reported withdrawing their supplemental new drug application, or sNDA, for Velcade, or bortezomib, to be injected in combination with rituximab in the treatment of patients suffering from relapsed follicular lymphoma. The company said the decision was made after discussions with external advisors and with the US Food and Drug Administration, or FDA, following the presentation of results from the LYM-3001 clinical trial at the American Society of Hematology.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Efficacy of dose-reduced lenalidomide in patients with refractory or recurrent multiple myeloma.

Conclusion: In conclusion, dose-reduced lenalidomide is an effective and well tolerated treatment for patients with recurrent or refractory MM who cannot tolerate full doses.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Maintenance therapy with rituximab prolongs the progression free survival in follicular lymphoma. Results from the PRIMA trial.

Maintenance therapy with rituximab prolongs the progression free survival in follicular lymphoma. Results from the PRIMA trial. | Veille Pharma | Scoop.it

Follicular lymphoma (FL) is the most common indolent lymphoma in the Western countries. It is considered rarely curable with conventional chemotherapy due to its tendency to relapse. FL maintains sensitivity to different chemotherapeutic agents for several years but ultimately becomes resistant or transforms into a high-grade lymphoma. The median survival has been in the range of 8 to 10 years.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.

These clinical outcomes. In conclusion, del(17p) defined a patient group associated with short survival in myeloma, and although thalidomide induction therapy was associated with improved response rates, it did not impact OS, suggesting that alternative therapeutic strategies are required for this group.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Nouvelle politique de l’Afssaps en matière d’Autorisations Temporaires d’Utilisations (ATU) : informations sur l’accès précoce des patients à un nouveau traitement du myélome multiple réfractaire

L’Afssaps a rencontré le laboratoire Celgene, en présence de l’Association Française des Malades du Myélome Multiple (AF3M), de l’Intergroupe Francophone du Myélome (IFM) et de l’organisme représentant les entreprises du médicament (LEEM), au sujet d’un traitement en cours de développement : le pomalidomide pour le traitement du myélome multiple (MM) réfractaire.

Les patients, qui ne peuvent être inclus dans les essais cliniques sur ce médicament, actuellement menés en France par Celgene et les équipes de recherche de l’IFM, et qui ne répondent pas ou plus aux traitements déjà disponibles, pourront être traités par pomalidomide via le dispositif d’Autorisation Temporaire d’Utilisation (ATU). Le laboratoire Celgene s’est engagé à déposer, à la fin du mois, une demande d’ATU de cohorte qui permettra un encadrement optimal de l’utilisation du produit et une équité d’accès. De son côté, l’Afssaps examinera les données supportives de cette demande, dans un délai de deux mois. D’ici là, des ATU nominatives pourront être accordées dans des situations d’urgence thérapeutique.

Lorsqu’ils sont éligibles, les patients seront préférentiellement inclus dans les essais cliniques. De plus, le laboratoire Celgene prévoit d’élargir l’accès dans un nouvel essai qui pourrait être mis en place dès que possible, lorsque les essais en cours auront inclus suffisamment de patients.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myelom...

We assessed efficacy, safety and renal impairment (RI) reversal in untreated multiple myeloma patients treated with bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide (VMPT-VT) maintenance versus bortezomib-melphalan-prednisone (VMP).

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Multiple Myeloma Research Foundation Announces Millennium as First Industry Partner in Innovative Collaboration to Advance Personalized Medicine for Multiple Myeloma

Multiple Myeloma Research Foundation Announces Millennium as First Industry Partner in Innovative Collaboration to Advance Personalized Medicine for Multiple Myeloma | Veille Pharma | Scoop.it

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a multi-year collaboration with Millennium: The Takeda Oncology Company to advance the MMRF’s emerging research program in personalized medicine. Both organizations believe the MMRF’s Personalized Medicine Initiative program will enable the biological segmentation of patients and accelerate the development of new, targeted treatments and potentially curative approaches for multiple myeloma. Millennium is the first pharmaceutical company to join the MMRF in advancing this new initiative.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Bortezomib drug may also treat pulmonary fibrosis or scleroderma

A drug used to treat cancer may also be effective in diseases that cause scarring of the internal organs or skin, such as pulmonary fibrosis or scleroderma.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Multiple Myeloma Research Foundation (MMRF) Announces First Patient Enrolled in Landmark 1000-Patient Study, with Four World-Class Cancer Centers as First Clinical Sites

Multiple Myeloma Research Foundation (MMRF) Announces First Patient Enrolled in Landmark 1000-Patient Study, with Four World-Class Cancer Centers as First Clinical Sites | Veille Pharma | Scoop.it

The Multiple Myeloma Research Foundation (MMRF) today announced that the first patient has enrolled in a landmark 1000-patient study designed to uncover the molecular segments and variations of multiple myeloma. The study is the centerpiece of the MMRF’s Personalized Medicine Initiative, CoMMpass (Relating Clinical Outcomes in MM to Personal Assessment of Genetic Profile) to rapidly propel the translation of these insights into new clinical strategies and therapeutic breakthroughs for patients.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Une meilleure connaissance du profil génétique du myélome ...

L'étude des caractéristiques génétiques du myélome multiple pourrait permettre une meilleure compréhension de cette forme de cancer du sang et la mise au point de nouveaux traitements ciblés.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Researchers gain insight into MM drug resistance

Researchers gain insight into MM drug resistance | Veille Pharma | Scoop.it

Researchers have employed a technique that allows them to monitor and quantify the proteins involved in acquired drug resistance in multiple myeloma.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.

Overexpression of the transcription factor interferon regulatory factor-4 (IRF4), which is common in multiple myeloma (MM), is associated with poor prognosis.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Neupogen And Neulasta Show Comparable Activity In Multiple Myeloma Patients After Stem Cell Transplantation

Neupogen And Neulasta Show Comparable Activity In Multiple Myeloma Patients After Stem Cell Transplantation | Veille Pharma | Scoop.it

Results of a recent Italian study show that Neupogen and Neulasta are comparable in efficacy and safety for the prevention and treatment of low white blood cell counts in multiple myeloma patients receiving outpatient stem cell transplants.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Onyx Pharma submits NDA for carfilzomib in relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced that it has completed the New Drug Application (NDA) submission to the US Food and Drug Administration (US FDA) under the accelerated approval process for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma. In addition, Onyx has requested priority review of the application, which reduces the time the US FDA takes to review a new drug application.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Study finds early potential in GSK leukaemia drug

Study finds early potential in GSK leukaemia drug | Veille Pharma | Scoop.it

n a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Istodax-Velcade-Dexamethasone Combination May Be Effective In Relapsed/Refractory Myeloma - The Myeloma Beacon

Istodax-Velcade-Dexamethasone Combination May Be Effective In Relapsed/Refractory Myeloma - The Myeloma Beacon | Veille Pharma | Scoop.it

Results of a small, Phase 1/2 Australian study indicate that a combination of Istodax, Velcade, and dexamethasone may be effective in relapsed and refractory multiple myeloma patients.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

MM Mobile – A review of the new app just for multiple myeloma physicians

MM Mobile – A review of the new app just for multiple myeloma physicians | Veille Pharma | Scoop.it

There is a new app, especially for physicians who treat multiple myeloma and it’s free. I just downloaded it and gave it a spin. It’s called MMand is comprised of 3 basic sections:

MM in the news (kind of like a daily Google alert shuttled directly into your phone)

A video archive featuring prominent voices in the MM community such as Dr. Ken Anderson from Harvard Medical School and Dr. Sundar Jagannath from Mt. Sinai Hospital in New York.

And a calculator section including ISS Staging and Createnine Clearance with suggested Zometa and Revlamid dosing.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients.

he combination of pegylated liposomal doxorubicin (PLD), bortezomib and dexamethasone has shown efficacy in the treatment of multiple myeloma (MM) patients.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Acetylon begins Phase I/IIa trial of ACY-1215 drug

Acetylon Pharmaceuticals has initiated a Phase I/IIa clinical trial of ACY-1215, an oral Class II histone deacetylase inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

MISE À JOUR RÉGLEMENTAIRE DE CELGENE AU SUJET DE REVLIMID®

MISE À JOUR RÉGLEMENTAIRE DE CELGENE AU SUJET DE REVLIMID® | Veille Pharma | Scoop.it

BOUDRY, Suisse--(BUSINESS WIRE)--Celgene International Sàrl (NASDAQ : CELG) a été notifié aujourd’hui que le Comité des médicaments à usage humain (CHMP) de l’Union européenne avait, pour le compte de l'Agence européenne du médicament, conclu une révision de REVLIMID® en vertu de l’article 20 et émis un avis favorable pour l’utilisation de REVLIMID en association avec la dexaméthasone pour le traitement des patients souffrant de myélome multiple et ayant reçu au moins une thérapie antérieure. La procédure en vertu de l’article 20 a été déclenchée suite au signalement d’un faible taux de deuxièmes malignités primaires dans le cadre d’études cliniques.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Possible lenalidomide-induced stevens-johnson syndrome during treatment for multiple myeloma.

Abstract :  Stevens-Johnson syndrome is a rare, severe cutaneous reaction most often associated with drug therapy. Lenalidomide is a derivative of thalidomide used in the treatment of multiple myeloma. We describe a case of Stevens-Johnson syndrome possibly induced by lenalidomide in a 73-year-old Caucasian female undergoing induction therapy for multiple myeloma.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Genetic Test Determines Multiple Myeloma Risk and Prognosis

Genetic Test Determines Multiple Myeloma Risk and Prognosis | Veille Pharma | Scoop.it
My PRSTM is a gene expression profile that identifies patients who are at risk for short remission and poor overall survival. Cells from the bone marrow of newly diagnosed patients are biopsied. These cells must be properly frozen and shipped to NeoGenomics Lab and once at the lab, over 70 genes are analyzed. Results are then compiled and sent back to the patient and provider in 7 – 10 days.
more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Sequential Treatment Using Velcade And Thalidomide Is Effective In High-Risk Multiple Myeloma Patients

Newly diagnosed, high-risk multiple myeloma patients can be effectively treated with sequential therapy, according to the results of a recent Phase 2 study. Participants in this study initially received a combination of Velcade, Doxil, and dexamethasone followed by a combination of thalidomide and dexamethasone, with the potential addition of Velcade to the second phase.

more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.

Thal-dex (TD) is an effective therapy for advanced MM. We evaluated TD as salvage treatment of MM patients at first relapse.

more...
No comment yet.